Fox Run Management L.L.C. Makes New Investment in Edwards Lifesciences Corporation $EW

Fox Run Management L.L.C. bought a new position in Edwards Lifesciences Corporation (NYSE:EW) during the 4th quarter, Holdings Channel.com reports. The fund bought 24,308 shares of the medical research company’s stock, valued at approximately $2,072,000. Edwards Lifesciences accounts for about 0.3% of Fox Run Management L.L.C.’s investment portfolio, making the stock its 27th largest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter worth about $25,000. Kohmann Bosshard Financial Services LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth about $28,000. Hilton Head Capital Partners LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth about $28,000. Hantz Financial Services Inc. boosted its position in Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after purchasing an additional 164 shares during the last quarter. Finally, Dorato Capital Management purchased a new position in Edwards Lifesciences in the fourth quarter worth about $29,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 0.1%

Shares of EW opened at $85.92 on Tuesday. The business’s 50 day moving average is $82.29 and its 200 day moving average is $83.07. The company has a market capitalization of $49.47 billion, a PE ratio of 45.70, a price-to-earnings-growth ratio of 2.16 and a beta of 0.87. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $89.48. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 620 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares in the company, valued at approximately $3,278,948.54. The trade was a 1.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 95,057 shares of company stock worth $7,874,217 over the last quarter. Company insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on EW. Truist Financial set a $90.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Barclays reaffirmed an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.